Company Name

Sinovac Biotech Ltd.

Stock Code

NASDAQ: SVA
Industry
Biotech

Company Overview

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines.  In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program.  The company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program.  Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), of which the EV71 vaccine is currently in Phase III clinical trials, pneumococcal conjugate, pneumococcal polysaccharides, and rubella.  Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines.

External Auditor

Ernst & Young LLP

Law Firm

Latham & Watkins LLP

Transfer Agent

Pacific Stock Transfer Company

Investor Relations

The Ruth Group

Principal Executive Office

No. 39, Shangdi Xi Road, Haidian District, Beijing 100085, P.R.C.
Tel:
+86-10-8289 0088
Fax:
+86-10-6296 6910
Email:
ir@sinovac.com
Website:

www.sinovac.com(English)   www.sinovac.com.cn(Chinese)

Copyright © 2001-2013 Sinovac Biotech Ltd. All Rights Reserved.

Add: No. 39 Shangdi Xi Road, Haidian District, Beijing, P.R.C. 100085 Supported by elongtian